Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

被引：4

作者：

Kong, Tiandong ^{[1
]}

Chen, Lu ^{[1
]}

Duan, Fangfang ^{[1
]}

Hou, Xiaoxia ^{[1
]}

Wang, Liuyan ^{[1
]}

Zhou, Hanli ^{[1
]}

Wang, Lanrong ^{[1
]}

Hu, Shanshan ^{[1
]}

Liu, Danna ^{[1
]}

机构：

[1] Henan Univ, Peoples Hosp Zhengzhou City 3, Canc Hosp, Zhengzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.8560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8560

引用

下载

页数：3

共 50 条

[41] Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
Zhang, W.
Yang, H.
Kong, T.
Han, B.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S536 - S536
[42] Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study.
Zhao, Yanbin
Zhang, Minghui
Liu, Jinglei
Pu, Haihong
Li, Yinghong
Li, Xin
Wang, Yan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience
Seoyoung Lee
Hyo Sup Shim
Beung-Chul Ahn
Sun Min Lim
Hye Ryun Kim
Byoung Chul Cho
Min Hee Hong
Cancer Immunology, Immunotherapy, 2022, 71 : 1093 - 1101
[44] First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
Lijuan Li
Dan Yang
Yanmei Min
Anyan Liao
Jing Zhao
Leilei Jiang
Xin Dong
Wei Deng
Huiming Yu
Rong Yu
Jun Zhao
Anhui Shi
BMC Cancer, 23
[45] Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience
Lee, Seoyoung
Shim, Hyo Sup
Ahn, Beung-Chul
Lim, Sun Min
Kim, Hye Ryun
Cho, Byoung Chul
Hong, Min Hee
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1093 - 1101
[46] Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer (SCLC): Final results.
Sharma, Neelesh
Pennell, Nathan A.
Halmos, Balazs
Ma, Patrick C.
Dowlati, Afshin
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[47] A Phase II Single-Arm Trial of Apatinib as Maintenance Treatment Following First-Line Chemotherapy in Extensive Stage Small Cell Lung Cancer
Teng, F.
Xing, P.
Wang, Y.
Hu, X.
Lin, L.
Li, J.
Hao, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1190 - S1190
[48] Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study
Kong, Fanming
Wang, Ziwei
Wang, Na
Zhang, Dou
Liao, Dongying
Zhang, Jing
Sun, Yidan
Zhang, Haojian
Jia, Yingjie
AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (08): : 3679 - 3685
[49] Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08)
Frueh, Martin
Cathomas, Richard
Siano, Marco
Tscherry, Gregor
Zippelius, Alfred
Mamot, Christoph
Erdmann, Andreas
Krasniqi, Fatima
Rauch, Daniel
Simcock, Mathew
Kuettel, Erika
Fustier, Pierre
Pless, Miklos
CLINICAL LUNG CANCER, 2013, 14 (01) : 34 - 39
[50] Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer
Reck, Martin
Horn, Leora
Novello, Silvia
Barlesi, Fabrice
Albert, Istvan
Juhasz, Erzsebet
Kowalski, Dariusz
Robinet, Gilles
Cadranel, Jacques
Bidoli, Paolo
Chung, John
Fritsch, Arno
Drews, Uta
Wagner, Andrea
Govindan, Ramaswamy
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 701 - 711

← 1 2 3 4 5 →